Last update Dec. 21, 2022
Very Low Risk
Antiretroviral. It is a nucleoside reverse transcriptase inhibitor (NRTI) with antiviral activity against HIV-1 and hepatitis B virus. Indicated for the treatment of HIV infection and AIDS and hepatitis B (HB). Administration together with other oral antiretrovirals in one daily dose.
Although it is concentrated in breast milk, it reaches a low, clinically insignificant concentration in breast milk (Aebi 2022, Waitt 2018 & 2017, Mugwanya 2016, Benaboud 2011), much lower (2% to 4%) than the dose used in newborns and infants. (Mugwanya 2016)
No problems have been observed in infants whose mothers were taking it, except for mild diarrhea in 4% of cases. (Mugwanya 2016)
The plasma levels of these infants were undetectable or very low, less than 20% of maternal plasma levels. (Aebi 2022, Waitt 2018 y 2017, Mugwanya 2016)
Authorized use in newborns and infants. The dosage in infants older than 3 months is 6 mg/kg/day and half from birth to that age. (Ribera 2011)
Its use in breastfeeding mothers is considered safe for both HIV and HB treatment and pre-exposure prophylaxis. (Mugwanya 2017, Seidman 2017)
We do not have alternatives for Emtricitabine (FTC) since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM